View in EDS HTML Full Text PDF Full Text

Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.

Saved in:

Bibliographic Details
Title:	Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
Authors:	Mansell, Kerry¹ (AUTHOR), Bhimji, Hishaam¹ (AUTHOR), Eurich, Dean² (AUTHOR), Mansell, Holly¹ (AUTHOR)
Source:	BMC Health Services Research. 12/18/2019, Vol. 19 Issue 1, p1-3. 3p. 1 Chart, 1 Graph.
Database:	Academic Search Ultimate
Full text is not displayed to guests. Login for full access.

Description
ISSN:	14726963
DOI:	10.1186/s12913-019-4829-z